**Author details**

Karine Cohen Solal1 and Ahmed Lasfar1,2\*

1 Department of Pharmacology and Toxicology, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ, United States

2 Rutgers-Cancer Institute of New Jersey, Rutgers University, New Brunswick, NJ, United States

\*Address all correspondence to: lasfarah@gmail.com

© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**7**

*Introductory Chapter: Melanoma and Therapeutic Perspectives*

cell level: What next? Biochim Biophys Acta Rev Cancer. 2020 Dec;1874(2): 188440. doi: 10.1016/j.bbcan.2020. 188440. Epub 2020 Sep 29. PMID:

[8] Tangella LP, Clark ME, Gray ES. Resistance mechanisms to targeted therapy in BRAF-mutant melanoma - A mini review. Biochim Biophys Acta Gen Subj. 2021 Jan;1865(1):129736. doi: 10.1016/j.bbagen.2020.129736. Epub 2020 Sep 18. PMID: 32956754.

[9] Mazurkiewicz J, Simiczyjew A, Dratkiewicz E, Ziętek M, Matkowski R, Nowak D. Stromal Cells Present in the Melanoma Niche Affect Tumor Invasiveness and Its Resistance to Therapy. Int J Mol Sci. 2021 Jan

7;22(2):529. doi: 10.3390/ijms22020529. PMID: 33430277; PMCID: PMC7825728.

[10] Kakadia S, Yarlagadda N, Awad R, Kundranda M, Niu J, Naraev B, Mina L, Dragovich T, Gimbel M, Mahmoud F. Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administrationapproved targeted therapy in advanced melanoma. Onco Targets Ther. 2018 Oct 17;11:7095-7107. doi: 10.2147/OTT. S182721. PMID: 30410366; PMCID:

[11] Alqathama A. BRAF in malignant melanoma progression and metastasis: potentials and challenges. Am J Cancer Res. 2020 Apr 1;10(4):1103-1114. PMID: 32368388; PMCID: PMC7191094.

[12] Tanda ET, Vanni I, Boutros A, Andreotti V, Bruno W, Ghiorzo P, Spagnolo F. Current State of Target Treatment in BRAF Mutated Melanoma. Front Mol Biosci. 2020 Jul 14;7:154. doi: 10.3389/fmolb.2020.00154. PMID: 32760738; PMCID: PMC7371970.

[13] Ray A, Kunhiraman H, Perera RJ.

The Paradoxical Behavior of

PMC6200076.

33007433.

*DOI: http://dx.doi.org/10.5772/intechopen.97102*

[1] Siegel RL, Miller KD and Jemal A: Cancer statistics, 2018. CA Cancer J

[2] Leonardi GC, Falzone L, Salemi R, Zanghì A, Spandidos DA, McCubrey JA, Candido S and Libra M: Cutaneous melanoma: From pathogenesis to therapy (Review). Int J Oncol. 52:1071-

[3] Jenkins RW, Fisher DE. Treatment of Advanced Melanoma in 2020 and Beyond. J Invest Dermatol. 2021 Jan;141(1):23-31. doi: 10.1016/j. jid.2020.03.943. Epub 2020 Apr 5. PMID: 32268150; PMCID: PMC7541692.

[4] Massimo Ralli, Andrea Botticelli, Irene Claudia Visconti, Diletta

Alessandro Lambiase, Marco de Vincentiis, Antonio Greco,

2020, Article ID 9235638, 12

[6] Falcone I, Conciatori F,

pages, 2020.

Angeletti, Marco Fiore, Paolo Marchetti,

"Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions", Journal of Immunology Research, vol.

[5] Leonardi GC, Candido S, Falzone L, Spandidos DA, Libra M. Cutaneous melanoma and the immunotherapy revolution (Review). Int J Oncol. 2020 Sep;57(3):609-618. doi: 10.3892/

ijo.2020.5088. Epub 2020 Jun 25. PMID: 32582963; PMCID: PMC7384846.

Bazzichetto C, Ferretti G, Cognetti F, Ciuffreda L, Milella M. Tumor Microenvironment: Implications in Melanoma Resistance to Targeted Therapy and Immunotherapy. Cancers (Basel). 2020 Oct 6;12(10):2870. doi: 10.3390/cancers12102870. PMID: 33036192; PMCID: PMC7601592.

[7] Liguoro D, Fattore L, Mancini R, Ciliberto G. Drug tolerance to target therapy in melanoma revealed at single

**References**

Clin. 68:7-30.

1080. 2018.

*Introductory Chapter: Melanoma and Therapeutic Perspectives DOI: http://dx.doi.org/10.5772/intechopen.97102*
